Fairmount Funds Management LLC

October 16, 2026

CBIO Announces New Clinical Trial Milestones for CR-001. Crescent Biopharma said it is enrolling patients in the standard‑of‑care chemotherapy arms of its global Phase 1/2 ASCEND trial for CR‑001, a PD‑1 × VEGF bispecific antibody. The company also began additional antibody‑drug‑conjugate combination studies with CR‑001. These steps indicate progress in the drug’s development and broaden its potential clinical applications.

September 7, 2026

HC Wainwright Reiterates $120 Target on Oruka. HC Wainwright maintained its buy rating on Oruka Therapeutics, keeping its price target at $120. The firm continues to see the company favorably despite recent trading levels well below that target. The analyst consensus average for the stock stands at $153.75, with estimates ranging from $102 to $200.

October 6, 2026

Spyre Therapeutics Launches $350M Public Offering, Stock Drops. Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.

October 17, 2026

Roche wins FDA approval for home thyroid eye disease therapy. Roche received FDA approval for the first at-home treatment for thyroid eye disease, a development relevant to Viridian Therapeutics as it operates in the same therapeutic space. While Viridian's stock is currently trading near its 52-week low, analysts maintain an average price target significantly higher than the current market price. The news highlights competitive dynamics in the thyroid eye disease market that investors may be monitoring.

October 8, 2026

Cogent Biosciences: Long-term performance review published. Benzinga published an article analyzing the value of a $1,000 investment in Cogent Biosciences made five years ago. This piece focuses on historical returns rather than new corporate developments or immediate market catalysts. The stock is currently trading near its 52-week low, with technical indicators showing recent downward pressure.

October 13, 2026

ZBIO releases Phase 3 Obexelimab data, plans MS trial presentations. The company released new Phase 3 results for its Obexelimab program in IgG4‑related disease, which were presented at a recent international symposium. The data release coincided with a 5.1% share decline. Zenas also announced upcoming virtual presentations of Orelabrutinib data for multiple sclerosis at MSToronto2026 and a broader R&D webcast. Analyst HC Wainwright kept its $44 price target, reinforcing its view on the stock.

October 13, 2026

DMRA Shares Rise Amid Valuation Debate. Damora Therapeutics shares have climbed recently, drawing attention to potential overvaluation relative to book value. While the stock is trading near its 52-week low, analyst targets remain significantly higher than the current price. This divergence highlights a split between short-term technical weakness and long-term fundamental expectations.

September 7, 2026

Jade Biosciences Schedules Conference Participation. Jade Biosciences has announced its participation in upcoming industry conferences. Such events typically provide opportunities for company leadership to engage with institutional investors and discuss business developments. The stock currently trades within its 52-week range, with analysts maintaining price targets significantly above current levels.

October 8, 2026

DNTH Highlighted by Benzinga and Announces Nasdaq Inducement Grants. Dianthus Therapeutics was named one of the top three health‑care stocks in a recent Benzinga feature that looks at companies that could help improve a portfolio this quarter. The company also disclosed that it will issue inducement grants under Nasdaq Listing Rule 5635(c)(4), a filing that relates to compliance with Nasdaq’s listing standards. Both items raise the company’s public profile and address regulatory requirements.